Controversy in treatment of advanced ovarian cancer

The Lancet Oncology

Volumn 14, Issue 10, 2013, Pages 920-921

  Scambia, Giovanni ^a   Salutari, Vanda ^a   Amadio, Giulia ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADVANCED CANCER; ALOPECIA; CANCER PROGNOSIS; CANCER STAGING; CYTOREDUCTIVE SURGERY; DOSAGE SCHEDULE COMPARISON; FEBRILE NEUTROPENIA; HUMAN; LETTER; LONG TERM SURVIVAL; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 84882969396     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70391-7     Document Type: Letter

References (8)

1. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011, 365:2473-2483. Gynecologic Oncology Group.
2. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011, 365:2484-2496. ICON7 Investigators.
3. Norton L Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 2001, 6(suppl 3):30-35.
4. Van der Burg ME, Janssen JT, Ottevanger PB, et al. Multicenter randomized phase III trial of 3-weekly paclitaxel/platinum (PC3w) versus weekly paclitaxel/platinum (PCw) induction therapy followed by PC3w maintenance therapy in advanced epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 2009, 27(suppl 286s):15s.
5. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009, 374:1331-1338. for the Japanese Gynecologic Oncology Group.
6. Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013, 14:1020-1026. for the Japanese Gynecologic Oncology Group.
7. Pignata S, Scambia G, Lauria R, et al. A randomized multicenter phase III study comparing weekly versus every 3 weeks carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicenter Italian Trials in Ovarian Cancer (MITO-7)-European Network of Gynaecological Oncological Trial Groups (ENGOT-ov-10) and Gynecologic Cancer Intergroup (GCIG) trial. Proc Am Soc Clin Oncol 2013, 31(suppl). abstr LBA5501.
8. Bell D, Berchuch A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. Cancer Genome Atlas Research Network.